Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kwang-Su Park

Showing results (11-20 of 56) with videos related to

Pageof 6
Sort By:
Nature Reviews. Cancer|June 16, 2021
Advancing targeted protein degradation for cancer therapyBrandon Dale, Meng Cheng, Kwang-Su Park, et al.
ACS Applied Materials & Interfaces|November 1, 2016
Bioinorganic Nanohybrid Catalyst for Multistep Synthesis of Acetaminophen, an AnalgesicBoi Hoa San, Subramaniyam Ravichandran, Kwang-Su Park, et al.
European Journal of Medicinal Chemistry|January 31, 2024
Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2Julia Velez, Brandon Dale, Kwang-Su Park, et al.
Journal of Medicinal Chemistry|November 25, 2010
Enhanced stability and intracellular accumulation of quercetin by protection of the chemically or metabolically susceptible hydroxyl groups with a pivaloxymethyl (POM) promoietyMi Kyoung Kim, Kwang-Su Park, Chaewoon Lee, et al.
Journal of Medicinal Chemistry|July 27, 2022
Discovery of a First-in-Class Degrader for Nuclear Receptor Binding SET Domain Protein 2 (NSD2) and Ikaros/AiolosFanye Meng, Chenxi Xu, Kwang-Su Park, et al.
Applied Microbiology and Biotechnology|December 18, 2014
Metabolic engineering of Escherichia coli for the biosynthesis of flavonoid-O-glucuronides and flavonoid-O-galactosideSo Yeon Kim, Hye Rin Lee, Kwang-Su Park, et al.
Pharmaceutics|April 26, 2025
PROTAC Delivery Strategies for Overcoming Physicochemical Properties and Physiological Barriers in Targeted Protein DegradationEndry Wahyu Syahputra, Hyunji Lee, Hyukjun Cho, et al.
Bioorganic & Medicinal Chemistry Letters|August 28, 2010
7-O-Arylmethylgalangin as a novel scaffold for anti-HCV agentsHyo Seon Lee, Kwang-su Park, Chaewoon Lee, et al.
Chemical & Pharmaceutical Bulletin|December 5, 2017
A Novel Probe with a Chlorinated α-Cyanoacetophenone Acceptor Moiety Shows Near-Infrared Fluorescence Specific for Tau FibrilsKwang-Su Park, Kyungha Yoo, Mi Kyoung Kim, et al.
Journal of Medicinal Chemistry|April 12, 2024
Discovery and Characterization of a Novel Cereblon-Recruiting PRC1 Bridged PROTAC DegraderMd Kabir, Lihuai Qin, Kaixiu Luo, et al.
Pageof 6

Showing results (11-20 of 56) with videos related to

Sort By:
Pageof 6
Nature Reviews. Cancer|June 16, 2021
Advancing targeted protein degradation for cancer therapyBrandon Dale, Meng Cheng, Kwang-Su Park, et al.
ACS Applied Materials & Interfaces|November 1, 2016
Bioinorganic Nanohybrid Catalyst for Multistep Synthesis of Acetaminophen, an AnalgesicBoi Hoa San, Subramaniyam Ravichandran, Kwang-Su Park, et al.
European Journal of Medicinal Chemistry|January 31, 2024
Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2Julia Velez, Brandon Dale, Kwang-Su Park, et al.
Journal of Medicinal Chemistry|November 25, 2010
Enhanced stability and intracellular accumulation of quercetin by protection of the chemically or metabolically susceptible hydroxyl groups with a pivaloxymethyl (POM) promoietyMi Kyoung Kim, Kwang-Su Park, Chaewoon Lee, et al.
Journal of Medicinal Chemistry|July 27, 2022
Discovery of a First-in-Class Degrader for Nuclear Receptor Binding SET Domain Protein 2 (NSD2) and Ikaros/AiolosFanye Meng, Chenxi Xu, Kwang-Su Park, et al.
Applied Microbiology and Biotechnology|December 18, 2014
Metabolic engineering of Escherichia coli for the biosynthesis of flavonoid-O-glucuronides and flavonoid-O-galactosideSo Yeon Kim, Hye Rin Lee, Kwang-Su Park, et al.
Pharmaceutics|April 26, 2025
PROTAC Delivery Strategies for Overcoming Physicochemical Properties and Physiological Barriers in Targeted Protein DegradationEndry Wahyu Syahputra, Hyunji Lee, Hyukjun Cho, et al.
Bioorganic & Medicinal Chemistry Letters|August 28, 2010
7-O-Arylmethylgalangin as a novel scaffold for anti-HCV agentsHyo Seon Lee, Kwang-su Park, Chaewoon Lee, et al.
Chemical & Pharmaceutical Bulletin|December 5, 2017
A Novel Probe with a Chlorinated α-Cyanoacetophenone Acceptor Moiety Shows Near-Infrared Fluorescence Specific for Tau FibrilsKwang-Su Park, Kyungha Yoo, Mi Kyoung Kim, et al.
Journal of Medicinal Chemistry|April 12, 2024
Discovery and Characterization of a Novel Cereblon-Recruiting PRC1 Bridged PROTAC DegraderMd Kabir, Lihuai Qin, Kaixiu Luo, et al.
Pageof 6